title: [Tyrosine kinases as targets of cancer therapy: from disbelief to Lazarus responses].
abstract: Tyrosine kinase inhibitors have proved to be effective and well-tolerated anticancer drugs. They are used successfully even for the treatment of cancers that exhibit only modest treatment outcomes with conventional cytotoxic drugs. Treatment responses may continue for several years, and sometimes tyrosine kinases are beneficial also as adjuvant therapy following cancer operation. A requirement for the drugs to be effective is, however, that the kinases to be inhibited play a central role in the development and progression of the tumor. In addition, the development of acquired drug resistance during treatment is common.
authors.affiliation: HYKS, syöpätautien klinikka.
authors.forename: Heikki
authors.initials: H
authors.lastname: Joensuu
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases